GSK shrinks Scynex­is deal af­ter de­lay in com­mer­cial­iza­tion of an­ti­fun­gal drug

Scynex­is will get less mon­ey in a mul­ti­mil­lion-dol­lar li­cense agree­ment with Glax­o­SmithK­line af­ter po­ten­tial cross-con­t­a­m­i­na­tion in the man­u­fac­tur­ing of its an­ti­fun­gal drug de­layed com­mer­cial­iza­tion. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.